PSTV’s Game-Changer: UnitedHealthcare Backs CNSide® Assay!

Introduction

Plus Therapeutics, Inc. (NASDAQ: PSTV) is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for aggressive central nervous system (CNS) cancers (^[1]). The company gained significant attention after its subsidiary CNSide Diagnostics, LLC secured a national coverage agreement with UnitedHealthcare (NYSE: UNH), effective September 15, 2025, to provide the CNSide® cerebrospinal fluid tumor cell assay to over 51 million covered lives across the U.S. (^[1]). CNSide is a laboratory-developed test (LDT) designed to detect and characterize tumor cells in the cerebrospinal fluid of patients with metastatic cancer in the CNS (such as leptomeningeal metastases, or LM) (^[1]). The assay has demonstrated 92% sensitivity and 95% specificity, influencing treatment decisions in 90% of cases, with over 11,000 tests performed at 120+ U.S. cancer centers since 2020 (^[1]). UnitedHealthcare’s backing is viewed as a potential game-changer for Plus Therapeutics – it not only validates the clinical utility of CNSide, but also paves the way for broad insurance reimbursement, potentially accelerating adoption and revenue generation.

CNSide’s national coverage by the largest private insurer marks a pivotal milestone for PSTV. The test offers a much-needed upgrade over century-old standard CSF cytology, enabling more sensitive detection and monitoring of CNS tumor spread (^[2]) (^[2]). Plus Therapeutics’ management has emphasized the synergy between its diagnostics and therapeutics: CNSide can identify and track cancer cells in the CNS, complementing the company’s pipeline of radiotherapy candidates for LM and recurrent glioblastoma (GBM) (^[1]) (^[2]). In fact, CNSide’s prior real-world adoption and multiple peer-reviewed studies have established its value, and now with UnitedHealthcare’s coverage, Plus plans a full U.S. commercial rollout beginning in Texas in late 2025 (^[2]). This strategic bet – combining a cutting-edge diagnostic platform with novel radiotherapeutics (like lead candidate Rhenium-186 Nanoliposome “REYOBIQ™” for LM) – could potentially transform Plus Therapeutics from a purely R&D-stage biotech into an operational, revenue-generating company (^[3]) (^[3]).

Dividend Policy & Yield

Plus Therapeutics does not pay any dividend and has no history of distributing cash to shareholders. The company explicitly states that it has “never paid cash dividends… and does not anticipate paying cash dividends… in the foreseeable future,” opting instead to reinvest any future earnings back into the business (^[4]) (^[4]). This policy is typical for clinical-stage biotech companies like PSTV, which incur net losses and prioritize funding research and commercialization efforts over shareholder payouts. Consequently, PSTV’s dividend yield is 0%, and income-focused investors should not expect any near-term dividends.

(AFFO/FFO metrics are not applicable in this case, as Plus Therapeutics is not a REIT or income-producing property company but a development-stage biotech with negative cash flows.)

Leverage & Debt Maturities

Despite its small size, Plus Therapeutics has managed its leverage relatively conservatively. The company historically carried a venture term loan from Oxford Finance LLC, originally $17.7 million, which had been paid down to $0.7 million principal by year-end 2023 (^[5]). A final balloon payment of about $3.3 million in deferred interest was coming due in June 2024 (^[5]). Rather than expending precious cash on this lump sum, PSTV entered a debt restructuring in early 2024: it secured a new credit facility (via Pershing Capital) at a lower interest rate with flexible terms, deferring principal repayments into 2025 and beyond (^[5]). This refinancing effectively reduced 2024 cash burn by $3.7 million and alleviated near-term liquidity pressure (^[5]) (^[5]). As a result, Plus was able to push out its debt maturity and preserve cash for operations. The restructured debt facility should cover the remaining Oxford loan obligation and extend the maturity, though specific new maturity dates were not publicly disclosed (it is expected that principal will now come due in 2025/2026+ instead of mid-2024).

Aside from this term loan, Plus Therapeutics relies heavily on non-dilutive funding and equity rather than traditional debt. In fact, the company is the recipient of a $17.8 million grant award from the Cancer Prevention & Research Institute of Texas (CPRIT), which covers roughly two-thirds of development costs for its Rhenium-186 radiotherapeutic program (^[5]). In Q4 2023, Plus received $3.3 million of CPRIT grant revenue (an advance for year 2 of the award) and forecasts another $6.9 million in grant revenue during 2024 (^[5]). This grant effectively subsidizes R&D spending and does not have to be repaid as long as contract conditions are met. Other obligations on the balance sheet are minimal – the company has typical lease commitments for its Houston office/lab and no off–balance sheet arrangements or long-term purchase contracts beyond R&D collaborations (^[4]) (^[4]). Overall, Plus’s financial leverage is low, with only a few million dollars of debt (now restructured) and no significant debt maturities until at least 2025. This low-debt profile gives PSTV some flexibility, but it also means the company must continually raise equity or grant funding to finance its operations (since it cannot rely on debt for large cash needs in its current state).

Coverage and Cash Flow Coverage

Given its developmental stage, Plus Therapeutics does not generate positive earnings or cash flows, so traditional coverage ratios are weak or not meaningful. In 2024, the company’s operations incurred a $(14.7)$ million operating loss, and even after grant revenue offsets, the net loss was $(13.0)$ million (^[3]). Meanwhile, interest expense was only about $0.4 million for the year (^[4]) – reflecting the small remaining debt – but earnings were far too negative to cover even this modest interest cost. In other words, interest coverage (EBIT/interest) was negative in 2024, as EBIT was –$14.7M and no operating income existed to service debt. The company has been financing its interest and other fixed obligations out of its cash reserves and external funding.

On a cash flow basis, coverage of fixed charges is similarly tenuous. Plus used $12.9 million of cash for operating activities in 2023 (roughly in line with 2022’s burn) (^[4]), and that burn rate continued into 2024. The CPRIT grant and periodic equity infusions have been crucial to “cover” this cash burn. Notably, management projects that the UnitedHealthcare coverage and relaunch of CNSide will begin to generate revenue, potentially improving cash flow. However, until CNSide testing volumes ramp up significantly (and/or a partner is found for its therapeutics), Plus remains reliant on external financing to cover its expenses. In summary, there is currently no dividend to cover, and interest/fixed-charge coverage is effectively nil – a typical situation for a biotech in the pre-commercial phase.

Valuation and Comps

Traditional valuation metrics are challenging to apply to PSTV, given its lack of earnings and nascent revenue. The stock recently traded around $0.56 per share, which corresponds to a market capitalization near $40 million (^[6]). With negative earnings (trailing EPS was –$1.95 in 2024 (^[3])), P/E ratios are not meaningful. Price-to-sales is also not very informative; the company’s only “revenues” in 2023–2024 were grant revenues ($4.9M in 2023 and $5.8M in 2024) (^[3]) and no product sales yet. Even on a forward-looking basis, analysts would have to model potential CNSide assay sales, which are just beginning, and any partnership/licensing deals for therapeutics – all highly speculative at this stage.

One could consider price-to-book as a rough gauge: at December 31, 2024, Plus’s stockholders’ equity was only $3.6 million (down from $8.6M a year prior) (^[3]). Following a $15M private placement in Q1 2025, equity would have increased, but much of that cash will be consumed by ongoing trials and the CNSide launch. Even generously assuming ~$10–15M pro forma equity by late 2025, the market cap of ~$40M implies a Price/Book on the order of 3×–4×. This indicates investors are valuing PSTV well above its current tangible assets – essentially pricing in the future potential of its technology.

URGENT: Get “Trump\'s Secret Fund” — Learn How to Collect Royalty Checks

Limited report reveals the #1 American oil & gas royalty play that can start paying monthly — with just $50.

Mobile-friendly
Start w/ $50

Yes — Send My Report
Fast download • Instant access • Seats limited

For context, the total addressable market (TAM) for CNSide is substantial: Plus estimates the “underserved CNS cancer diagnostic” U.S. market at over $6 billion** (^[2]). If CNSide can penetrate even a fraction of this market (for example, diagnosing and monitoring the ~30% of cancer patients who develop CNS metastases (^[2])), annual revenues could scale into the hundreds of millions. Similarly, a successful therapeutic for leptomeningeal metastases or GBM could be a blockbuster given the high unmet need. By those yardsticks, a $40M market cap could appear very low – if PSTV executes perfectly. However, current valuation also reflects the high risks and early stage of these programs. It’s instructive to note that PSTV’s stock has been extremely volatile: it underwent a 1-for-50 reverse split in 2019 (^[7]) (^[7]) and still traded under $1.00 for much of 2023–2025, requiring creative financing to stay afloat (see Risks & Red Flags). In short, Plus Therapeutics is valued on future promise rather than present fundamentals. There are no close public comparables focused solely on CNS liquid biopsies and radiotherapeutics – the company straddles the biotech and diagnostic lab sectors. Investors must therefore weigh PSTV’s unique upside (first-mover advantage in a $6B niche, and proprietary radiotherapy platform) against its dilution risk and execution uncertainties, rather than relying on P/E or P/FFO multiples.

Risks, Red Flags, and Concerns

Investing in PSTV carries significant risks consistent with micro-cap biotech stocks, as well as some unique red flags stemming from the company’s history and capital structure:

– Ongoing Losses & Cash Burn: Plus Therapeutics is not yet profitable and continues to incur multi-million-dollar annual losses (net loss of $13.0M in 2024 (^[3])). The company’s cash balance was only $3.6M at 2024 year-end (^[3]) before financing activities, and even after the Q1 2025 $15M raise, the runway extends only into 2026 (^[3]). If CNSide’s rollout or other funding (grants/partners) do not cover the burn rate by then, further dilutive capital raises will be necessary, or the company could face a cash crunch. This dependence on external funding is a perennial risk; any delay in revenue ramp or trial progress could shorten the runway.

– Dilution & Complex Financings: A major red flag is the dilution risk PSTV has exhibited. The March 2025 financing, while providing $15M cash, came with extraordinarily dilutive warrant structures. In fact, prior to restructuring, the warrants from that deal could have led to issuance of up to 1.5 billion new shares – an astronomic dilution given the pre-deal share count (^[8]). Recognizing the threat to shareholder value, management negotiated a comprehensive restructuring in June 2025 to cancel those toxic warrants. The restructure eliminated the potential 1.5B share overhang, canceled ~25 million in pending share issuance, and amended the remaining warrants to a fixed ~36 million shares (at a 1:1 cashless exercise) (^[8]) (^[8]). While this move averted immediate catastrophic dilution, investors should note that 36M additional shares (about what is currently outstanding) remain issuable if those warrants are exercised. Moreover, under the restructuring agreement, 90% of any future capital raised (post-Jul 2025) must go toward buying out the March 2025 investors at a 15% premium to their $0.66/share price (^[8]). This provision, intended to compensate those investors, essentially makes raising new equity capital very costly for PSTV – a potential impediment to funding if substantial revenue doesn’t materialize soon. In summary, the company’s recent financing history signals risk: shareholders have been heavily diluted in the past (including a 1-for-50 reverse split in 2019 to maintain Nasdaq listing (^[7]) (^[7])), and dilution could recur if cash needs outstrip internal resources.

– Regulatory and Execution Risk: Both arms of Plus’s business face substantial execution challenges. On the therapeutics side, PSTV’s drug candidates (like REYOBIQ for LM and a GBM therapy) are still in early clinical phases. Drug development for CNS cancers is high-risk: trials can take years and may fail to show efficacy or safety. Setbacks in clinical trials or regulatory approval could derail the company’s radiotherapeutic pipeline. On the diagnostics side, launching CNSide at scale is not trivial either. Plus must successfully transition CNSide from Biocept’s lab to its own Houston facility and obtain CLIA certifications in multiple states (^[2]). The June 2025 update indicates Plus has been securing state lab licenses, proprietary reimbursement codes, and building a commercial team (^[2]) (^[2]). However, winning physician adoption and integrating into oncology practice takes time – even with UHC’s coverage, doctors will need to order the test and hospitals must send samples. Any hiccups in lab operations, reimbursement billing, or logistics could slow the uptake.

– Uncertainty in Insurance & Market Adoption: The UnitedHealthcare agreement is a strong positive, but coverage by one insurer does not guarantee universal coverage. Other major payors (e.g., Blue Cross networks, Aetna, Cigna) have yet to announce coverage for CNSide. Medicare coverage is also not yet confirmed – Medicare/Medicaid patients (common in cancer demographics) might not have access unless CMS approves reimbursement. The CNSide test’s momentum in the market will depend on broad payor adoption. If other insurers or Medicare are slow to follow UHC’s lead, Plus’s addressable patient pool could be limited, affecting revenue. Additionally, UnitedHealthcare’s coverage is effective as of Sep 15, 2025 (^[1]); it remains to be seen how quickly this translates to actual testing volume. There may be administrative lead time before claims can be processed at scale.

– Competitive and IP Risks: While CNSide is described as a proprietary, “gold standard” assay (^[9]), it was originally developed by Biocept – which only granted Plus a non-exclusive license in 2023 (^[9]) (^[9]). Plus secured an option for exclusivity in the radiotherapy field (for $1M by Jan 2025) (^[9]), and management has since referred to “acquiring” CNSide, suggesting they have exercised or expanded rights. Nonetheless, the initial non-exclusive nature raises some concern: in theory, Biocept (or others) could license or offer a similar CSF assay for non-radiotherapy uses, creating future competition in the diagnostic market. Moreover, other diagnostic companies or academic labs may develop alternative methods (e.g. cell-free tumor DNA assays in CSF) to compete in this emerging niche. PSTV will need to continually innovate and possibly secure full intellectual property control to fend off competition. The company’s strategy of combining the test with its therapy could be a moat, but if the therapy is delayed, CNSide will have to stand on its own in a competitive diagnostics landscape.

– History of Strategic Pivots: Investors should also note Plus Therapeutics’ corporate history. The company was formerly known as Cytori Therapeutics (and even earlier, MacroPore Biosurgery) and pivoted to its current CNS oncology focus in 2019 (^[10]). Cytori had spent years on unrelated biomedical projects (e.g. regenerative medicine and cell therapies) which did not gain commercial traction. This legacy of shifting business models and past setbacks may be viewed as a red flag regarding management’s track record. Current CEO Dr. Marc Hedrick led Cytori and continues to lead Plus; while he has successfully refocused the company on a compelling new platform, some investors may remain cautious given the prior value destruction (Cytori’s stock saw massive dilution and reverse splits). The critical question is whether this time will be different – i.e., can the CNSide + radiotherapeutics strategy deliver sustained results?

In sum, PSTV is a high-risk, high-reward story. Key risks include the need for continued external funding (with attendant dilution), execution risks in launching a lab service and advancing clinical trials simultaneously, and the uncertainty of market uptake and competitive dynamics. The recent financial maneuvers (to avert dilution and extend cash runway) were necessary moves, but they underscore how precarious the situation could have been. Prospective investors should carefully weigh these red flags against the company’s promising developments.

Open Questions & Future Outlook

The UnitedHealthcare coverage news undoubtedly boosts confidence in Plus Therapeutics’ vision, but it also raises several open questions going forward:

1. How quickly and widely will CNSide be adopted? UnitedHealthcare covers 51 million people, but what percentage of eligible patients will actually get the CNSide test? Will oncologists readily integrate it into standard practice for patients with suspected CNS metastases? The test had “widespread adoption” in a previous commercial run (^[2]), but translating that into consistent order volume (and revenue) under Plus’s stewardship is the next challenge. Moreover, can PSTV secure additional insurance coverage from other major payors or Medicare to unlock the full market? Early traction with UHC is promising, but broader coverage will be needed to approach the $6B TAM.

2. Can CNSide meaningfully shorten the path to profitability? In a June update, CEO Marc Hedrick expressed enthusiasm that launching CNSide under a “full commercial access strategy” will give Plus “an expedited path to both revenue and corporate profitability”, even as it continues R&D on therapeutics (^[2]). Is this optimism well-founded? The coming quarters will reveal how much revenue the assay can generate and whether it can offset the company’s ~$1M+ per month operating expenses. Achieving corporate profitability would likely require tens of millions in annual diagnostic revenue. This hinges on scaling up testing volumes in 2025–2026. If uptake is slower than expected, Plus might still need additional funding before reaching breakeven – testing the validity of that “expedited path” claim.

3. Will Plus’ cash runway suffice until self-sustainability? After the recent financing and debt restructure, management believes it has runway into 2026 (^[3]). However, this assumes certain milestones (grant inflows, CNSide sales, controlled spending). If, for instance, the planned Phase 2 trials for REYOBIQ (LM radiotherapeutic) demand more capital or if CNSide’s rollout requires additional investment (salesforce, lab expansion) before it pays for itself, PSTV could be forced back to the capital markets. With the current restriction that 90% of new raise proceeds go to redeem prior shares (^[8]), raising cash could be inefficient. Will Plus be able to avoid another dilutive equity raise by generating sufficient internal cash flow? Or might it seek a strategic partnership (or even an acquisition by a larger diagnostics or pharma company) to bolster its resources?

4. How will the dual-focus strategy play out? Plus Therapeutics is essentially operating two businesses – a diagnostics service and a drug development pipeline – under one roof. This is an innovative approach (potentially offering a comprehensive solution for CNS metastases: diagnose and treat), but it also creates complexity. Can a small company successfully execute on both fronts simultaneously? The hiring of experienced diagnostics personnel for CNSide is a positive step (^[2]), but managing priorities and capital allocation between the diagnostic unit and the therapeutics R&D will be an ongoing balancing act. It’s worth asking whether, in the long run, Plus will remain a combined entity or if it might spin off or sell the CNSide diagnostics division (for example, if the assay becomes very successful, could it attract pure-play diagnostic companies?). Conversely, if the therapeutic pipeline shows breakthrough results, might Plus concentrate on that and partner out the diagnostics? The strategy to keep them integrated will be tested by execution and market responses over time.

5. What are the competitive and technological moats? As CNSide re-enters the market, how strong is its differentiation? The assay demonstrated clear advantages over old cytology (^[2]) (^[2]), but are there emerging alternatives (such as next-gen sequencing of CSF) that could compete in the future? Also, with Biocept having licensed it out, one wonders if Biocept or others could re-emerge in this space. Biocept’s decision to out-license CNSide for only $150K in stock (with a $1M option) (^[9]) suggests it lacked the resources to commercialize it – but not necessarily that the test itself lacked value. Now that Plus is proving the value with UHC’s endorsement, will any other labs try to develop similar CSF tests? How Plus defends its turf – perhaps through exclusivity agreements (if not already exercised) or by continuously improving the CNSide platform (adding molecular features, etc.) – will be important in maintaining its first-mover advantage.

In conclusion, PSTV stands at a crossroads: the UHC-backed launch of CNSide in 2025 could mark the beginning of a new chapter in which Plus Therapeutics transitions to a revenue-generating, more self-sufficient enterprise. If successful, the company would not only help fill a critical gap in CNS cancer care but also potentially fund its own drug development from diagnostic profits – a rare feat in biotech. However, investors should closely watch the execution of this rollout and the company’s financial maneuvers in the next 12–18 months. The story is compelling, but many of the questions above will need clear, positive answers for PSTV to truly be the “game-changer” its supporters hope for.

Sources: Plus Therapeutics SEC filings and press releases; UnitedHealthcare coverage announcement (^[1]) (^[1]); Company financial updates (^[5]) (^[5]); CNSide business update (^[2]) (^[2]); Financing restructuring news (^[8]) (^[8]); and other relevant disclosures as cited.

Sources

1. https://ir.plustherapeutics.com/news-releases/news-release-details/plus-therapeutics-announces-national-coverage-agreement
2. https://ir.plustherapeutics.com/news-releases/news-release-details/plus-therapeutics-provides-business-update-cnside-diagnostics/
3. https://globenewswire.com/news-release/2025/03/27/3051005/0/en/Plus-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Recent-Business-Highlights.html
4. https://sec.gov/Archives/edgar/data/1095981/000095017024025851/pstv-20231231.htm
5. https://ir.plustherapeutics.com/news-releases/news-release-details/plus-updates-financial-and-cash-guidance-2024
6. https://marketscreener.com/news/plus-therapeutics-announces-national-coverage-agreement-with-unitedhealthcare-insurance-company-for-ce7d58d2d180fe22
7. https://globenewswire.com/en/news-release/2019/07/29/1892764/0/en/Plus-Therapeutics-Inc-Announces-Nasdaq-Ticker-Symbol-Changes-and-Reverse-Stock-Split.html
8. https://ir.plustherapeutics.com/news-releases/news-release-details/plus-therapeutics-announces-comprehensive-restructuring-15
9. https://ir.plustherapeutics.com/news-releases/news-release-details/plus-therapeutics-enters-license-agreement-cerebrospinal-fluid
10. https://sec.gov/Archives/edgar/data/1095981/000095017023004099/pstv-20221231.htm

For informational purposes only; not investment advice.